In last trading session, Taysha Gene Therapies Inc (NASDAQ:TSHA) saw 3.99 million shares changing hands with its beta currently measuring 0.77. Company’s recent per share price level of $1.82 trading at $0.04 or 2.25% at ring of the bell on the day assigns it a market valuation of $373.20M. That closing price of TSHA’s stock is at a discount of -137.36% from its 52-week high price of $4.32 and is indicating a premium of 42.31% from its 52-week low price of $1.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.93 million shares which gives us an average trading volume of 2.14 million if we extend that period to 3-months.
For Taysha Gene Therapies Inc (TSHA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.10. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Taysha Gene Therapies Inc (NASDAQ:TSHA) trade information
Upright in the green during last session for gaining 2.25%, in the last five days TSHA remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $1.82 price level, adding 8.08% to its value on the day. Taysha Gene Therapies Inc’s shares saw a change of 5.20% in year-to-date performance and have moved 43.31% in past 5-day. Taysha Gene Therapies Inc (NASDAQ:TSHA) showed a performance of 9.64% in past 30-days. Number of shares sold short was 21.63 million shares which calculate 9.98 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8.5 to the stock, which implies a rise of 78.59% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 44. It follows that stock’s current price would drop -174.73% in reaching the projected high whereas dropping to the targeted low would mean a loss of -174.73% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -63.99% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -0.23% while estimates for its earnings growth in next 5 years are of 7.82%.
Taysha Gene Therapies Inc (NASDAQ:TSHA)’s Major holders
Insiders are in possession of 18.33% of company’s total shares while institution are holding 82.17 percent of that, with stock having share float percentage of 100.62%. Investors also watch the number of corporate investors in a company very closely, which is 82.17% institutions for Taysha Gene Therapies Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at TSHA for having 21.21 million shares of worth $47.51 million. And as of 2024-06-30, it was holding 9.1103 of the company’s outstanding shares.
The second largest institutional holder is RTW INVESTMENTS, LP, which was holding about 18.8 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.075 of outstanding shares, having a total worth of $42.11 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 4.85 shares of worth $8.82 million or 2.36% of the total outstanding shares. The later fund manager was in possession of 4.58 shares on Mar 31, 2025 , making its stake of worth around $8.34 million in the company or a holder of 2.23% of company’s stock.
